Literature DB >> 29071441

Kinetic characterization of the inhibition of protein tyrosine phosphatase-1B by Vanadyl (VO2+) chelates.

Jason Hon1, Michelle S Hwang1, Meara A Charnetzki1, Issra J Rashed1, Patrick B Brady1, Sarah Quillin1, Marvin W Makinen2.   

Abstract

Protein tyrosine phosphatases (PTPases) are a prominent focus of drug design studies because of their roles in homeostasis and disorders of metabolism. These studies have met with little success because (1) virtually all inhibitors hitherto exhibit only competitive behavior and (2) a consensus sequence H/V-C-X5-R-S/T characterizes the active sites of PTPases, leading to low specificity of active site directed inhibitors. With protein tyrosine phosphatase-1B (PTP1B) identifed as the target enzyme of the vanadyl (VO2+) chelate bis(acetylacetonato)oxidovanadium(IV) [VO(acac)2] in 3T3-L1 adipocytes [Ou et al. J Biol Inorg Chem 10: 874-886, 2005], we compared the inhibition of PTP1B by VO(acac)2 with other VO2+-chelates, namely, bis(2-ethyl-maltolato)oxidovanadium(IV) [VO(Et-malto)2] and bis(3-hydroxy-2-methyl-4(1H)pyridinonato)oxidovanadium(IV) [VO(mpp)2] under steady-state conditions, using the soluble portion of the recombinant human enzyme (residues 1-321). Our results differed from those of previous investigations because we compared inhibition in the presence of the nonspecific substrate p-nitrophenylphosphate and the phosphotyrosine-containing undecapeptide DADEpYLIPQQG mimicking residues 988-998 of the epidermal growth factor receptor, a relevant, natural substrate. While VO(Et-malto)2 acts only as a noncompetitive inhibitor in the presence of either subtrate, VO(acac)2 exhibits classical uncompetitive inhibition in the presence of DADEpYLIPQQG but only apparent competitive inhibition with p-nitrophenylphosphate as substrate. Because uncompetitive inhibitors are more potent pharmacologically than competitive inhibitors, structural characterization of the site of uncompetitive binding of VO(acac)2 may provide a new direction for design of inhibitors for therapeutic purposes. Our results suggest also that the true behavior of other inhibitors may have been masked when assayed with only p-nitrophenylphosphate as substrate.

Entities:  

Keywords:  Bis(acetylacetonato)oxidovanadium(IV); Protein tyrosine phosphatase-1B; Steady-state kinetics; Uncompetitive inhibition; VO(acac)2; Vanadyl (VO2+) chelates

Mesh:

Substances:

Year:  2017        PMID: 29071441      PMCID: PMC5671894          DOI: 10.1007/s00775-017-1500-1

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  49 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

Review 2.  PTP1B: a double agent in metabolism and oncogenesis.

Authors:  Shu-Chin Yip; Sayanti Saha; Jonathan Chernoff
Journal:  Trends Biochem Sci       Date:  2010-04-08       Impact factor: 13.807

3.  Purification of the major protein-tyrosine-phosphatases of human placenta.

Authors:  N K Tonks; C D Diltz; E H Fischer
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

Review 4.  The vanadyl ion: molecular structure of coordinating ligands by electron paramagnetic resonance and electron nuclear double resonance spectroscopy.

Authors:  M W Makinen; D Mustafi
Journal:  Met Ions Biol Syst       Date:  1995

5.  Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition.

Authors:  M Sarmiento; Y A Puius; S W Vetter; Y F Keng; L Wu; Y Zhao; D S Lawrence; S C Almo; Z Y Zhang
Journal:  Biochemistry       Date:  2000-07-18       Impact factor: 3.162

6.  Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate.

Authors:  G Huyer; S Liu; J Kelly; J Moffat; P Payette; B Kennedy; G Tsaprailis; M J Gresser; C Ramachandran
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

7.  Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design.

Authors:  Y A Puius; Y Zhao; M Sullivan; D S Lawrence; S C Almo; Z Y Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  Purification and characterization of T cell protein tyrosine phosphatase reveals significant functional homology to protein tyrosine phosphatase-1B.

Authors:  Yolanda Romsicki; Brian P Kennedy; Ernest Asante-Appiah
Journal:  Arch Biochem Biophys       Date:  2003-06-01       Impact factor: 4.013

9.  Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats.

Authors:  Violet G Yuen; Sanjay Bhanot; Mary L Battell; Chris Orvig; John H McNeill
Journal:  Can J Physiol Pharmacol       Date:  2003-11       Impact factor: 2.273

10.  Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV).

Authors:  Ming Li; Wenjun Ding; Bharat Baruah; Debbie C Crans; Ruilin Wang
Journal:  J Inorg Biochem       Date:  2008-06-20       Impact factor: 4.155

View more
  1 in total

Review 1.  Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus.

Authors:  Samuel Treviño; Alfonso Díaz; Eduardo Sánchez-Lara; Brenda L Sanchez-Gaytan; Jose Manuel Perez-Aguilar; Enrique González-Vergara
Journal:  Biol Trace Elem Res       Date:  2018-10-22       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.